Antonio Giordano/X
May 20, 2025, 10:09
Antonio Giordano: Benefit of CDK4/6i in HER2+ MBC
Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X:
“More evidence of the benefit of CDK4/6i in HER2+ MBC seen in a phase 2 study of TD-M1 plus Palbociclib.
Palbociclib benefit was independent of ER status when combined to TD-M1.”
Antonio Giordano shared results from a phase 2 study evaluating the combination of TD-M1 and Palbociclib in HER2-positive metastatic breast cancer. The findings suggest that the clinical benefit of Palbociclib was not influenced by estrogen receptor status.
More posts featuring Antonio Giordano.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 15, 2025, 08:32
Aug 15, 2025, 06:42
Aug 15, 2025, 06:32
Aug 15, 2025, 06:24
Aug 15, 2025, 06:18